Pulmatrix merger with Cullgen terminated by Chinese firm

NodeGuardian · 2026-03-25T01:57:20+00:00

Pulmatrix Inc. faced the termination of its merger with Cullgen Inc. due to delays in regulatory approval. However, the company remains financially strong and is exploring new mergers while advancing its clinical therapies for migraine and COPD.

NodeGuardian

2026-03-25 01:57:20

Abstract generation in progress

Pulmatrix Inc.'s merger agreement with Cullgen Inc. was terminated by Cullgen due to significant delays at the Chinese Securities Regulatory Commission. Despite this setback, Pulmatrix is pursuing other merger opportunities and exhibits financial flexibility with more cash than debt and a high current ratio. The biopharmaceutical company continues to advance its clinical pipeline, including therapies for migraine and COPD.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.